Elisabet de los Pinos is the founder and CEO at Aura Biosciences, an innovation-driven company focused on the development of drugs using tumor-targeted Pseudovirions. A breakthrough technology discovered at the National Cancer Institute (NCI), pseudovirions are a novel approach that harnesses the power of synthetic biology and viral evolution to develop first-in-class drugs for cancer patients. Prior to founding Aura, Eli worked at Eli Lilly’s Oncology Business Unit in Europe. Eli obtained much of her oncology experience during a fellowship at Mount Sinai School of Medicine Institute of Molecular Medicine in New York and at Georgetown School of Medicine in Washington, D.C. Later she worked as a post-doctoral fellow at the Institute of Cancer Research in London. Eli holds a magna cum laude Ph.D. in molecular biology from the University of Barcelona, an M.B.A. from IE Business School, and is a fellow of the Entrepreneurship Development Program at MIT Sloan School of Management. She is a member of the board of overseers at the Museum of Science in Boston. Eli’s awards include the “Top 40 Under 40” by the Boston Business Journal, “Mass High Tech Woman to Watch,” and “Technology Pioneer” by the World Economic Forum.
Elisabet de los Pinos
Founding CEO, Aura Biosciences